NCT01262469 - Evaluating Lapatinib + Capecitabine in Patients Aged 70 and Over With HER2 Metastatic Breast Cancer. | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 31, 2009

Primary Completion Date

December 31, 2011

Study Completion Date

November 30, 2013

Conditions

Metastatic Breast Cancer70 Years Old Patients and OverAfter One Line of Chemotherapy With Trastuzumab

Interventions

DRUG

lapatinib + capecitabine

"For Lapatinib: 5 tablets of 250 mg each, once daily, until disease progression or unacceptable toxicity occurence.~For Capecitabine: 850 mg/m2 twice a day from day 1 to 14 of cycle 1 and 1000 mg/m2 twice a day from day 1 to 14 of the next cycles."

Trial Locations (20)

13273

Institut Paoli Calmettes, Marseille

14076

Centre Francois Baclesse, Caen

29200

Institut Cancérologie- CENTRE HOSPITALIER BREST, Brest

31052

Institut Claudius Regaud, Toulouse

33000

Clinique Tivoli, Bordeaux

42328

Centre Hospitalier de Roanne, Roanne

44805

Centre Rene Gauducheau, Nantes

45100

Centre Hospitalier Orleans La Source, Orléans

49933

Centre Paul Papin, Angers

51100

Polyclinique de Courlancy, Reims

59020

Centre Oscar Lambret, Lille

60021

Centre Hospitalier de Beauvais, Beauvais

67065

Centre Paul Strauss, Strasbourg

75005

Institut Curie, Paris

75015

Hegp-Hopital Broussais, Paris

76038

Centre Henri Becquerel, Rouen

77405

Centre Hospitalier de Lagny-Sur-Marne, Lagny-sur-Marne

92210

Centre Rene Huguenin, Saint-Cloud

01012

Ch Fleyriat, Bourg-en-Bresse

06189

Centre Antoine Lacassagne, Nice